Omni Healthcare's Analgesic Drug Cetaprin Has a 40% Share in the Analgesics

Multiple Choice

Omni Healthcare's analgesic drug Cetaprin has a 40% share in the analgesics market in the country of Terrania. Its closest competitor, Febex, has a 25% share in the market, while four other analgesic brands split the remainder. Which statement indicates that Cetaprin is a cash cow according to the BCG matrix?

A) Omni Healthcare often takes money from other strategic business units to support Cetaprin.
B) A customer survey shows that Cetaprin users do not prefer it to other analgesics in the market.
C) The demand for analgesic drugs in the Terrania market is expected to remain stable.
D) Febex is rapidly gaining market share over Cetaprin due to aggressive marketing efforts.
E) The Terrania market for healthcare products is expanding rapidly.